Bexacat™ (bexagliflozin tablets)
Bexacat is a once-daily tablet alternative to insulin for treating feline diabetes. It lowers blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2) and results in effective glycemic control.
Why Choose Bexacat?
Bexacat gives your patients a needle-free alternative to insulin with an orally administered SGLT2 inhibitor.
The FIRST and ONLY non-insulin, orally administered tablet for feline diabetes.
Innovative SGLT2 inhibitor provides effective glycemic control without injections.
Minimal risk of hypoglycemia and no dosage changes during treatment.
Convenient, confusion-free, needle-free, once-daily flavored tablet.
Important Information about Bexacat
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Bexagliflozin
15 mg flavored oral tablet available in 30 ct and 90 ct sizes
Dosing Information
| - - For cats ≥ 6.6 lbs (3.0 kg) |
| Dosage - 1 tablet |
| Frequency - Once daily, approximately the same time each day |
| Method - Oral, with or without food |
| - | Dosage | Frequency | Method |
|---|---|---|---|
| For cats ≥ 6.6 lbs (3.0 kg) | 1 tablet | Once daily, approximately the same time each day | Oral, with or without food |
The search for an insulin alternative for feline diabetes is over.
Be one of the first to know when you can bring Bexacat into your clinic. Click the link below and sign up for product notifications.
Bexacat™ (bexagliflozin tablets) Resources
Patient Selection & Monitoring Detailer
Bexacat FAQs
Indication:
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Important Safety Information:
Before using this product, it is important to read the entire product insert, including the boxed warning. See package insert for full prescribing information. Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat. Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, diarrhea that is unresponsive to conventional therapy, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level. Bexacat should not be initiated in cats with pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function. Consult a physician in case of accidental ingestion by humans.